A Phase 2, Randomized, Double-blind Trial To Evaluate The Safety And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine In Healthy Infants
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2018
At a glance
- Drugs Pneumococcal vaccine conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
- 11 Oct 2018 Planned End Date changed from 26 Jan 2020 to 1 Feb 2020.
- 11 Oct 2018 Planned primary completion date changed from 26 Jan 2020 to 1 Feb 2020.
- 11 Oct 2018 Status changed from recruiting to active, no longer recruiting.